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Multidrug resistance in acute myeloid leukemia is of-
ten conferred by overexpression of P-glycoprotein, en-
coded by the MDR1 gene. We have characterized the key
regulatory steps in the development of multidrug resist-
ance in K562 myelogenous leukemic cells. Unexpectedly,
up-regulation of MDR1 levels was not due to transcrip-
tional activation but was achieved at two distinct post-
transcriptional steps, mRNA turnover and translational
regulation. The short-lived (half-life 1 h) MDR1 mRNA of
naı¨ve cells (not exposed to drugs) was stabilized (half-
life greater than 10 h) following short-term drug expo-
sure. However, this stabilized mRNA was not associated
with translating polyribosomes and did not direct P-
glycoprotein synthesis. Selection for drug resistance, by
long-term exposure to drug, led to resistant lines in
which the translational block was overcome such that
the stabilized mRNA was translated and P-glycoprotein
expressed. The absence of a correlation between steady-
state MDR1 mRNA and P-glycoprotein levels was not
restricted to K562 cells but was found in other lymphoid
cell lines. These findings have implications for the
avoidance or reversal of multidrug resistance in the
clinic.
MDR1 is the most common impediment to successful chem-
otherapy for a variety of cancers (1). The most frequent form of
drug resistance in relapsed acute leukemia is overexpression of
P-glycoprotein (2, 3). P-glycoprotein is a member of the ATP-
binding cassette superfamily of active transporters and func-
tions as an energy-dependent efflux pump that reduces the
intracellular concentration of cytotoxic compounds and, hence,
their toxicity. P-glycoprotein has a broad substrate specificity
and can confer resistance to a wide range of different cytotoxic
compounds (4).
Most pre-clinical and clinical efforts to overcome MDR aim to
modulate P-glycoprotein activity. However, clinical trials of
compounds that inhibit P-glycoprotein activity have had lim-
ited success and led to adverse pharmacokinetic side effects (1).
It may, therefore, be more appropriate to target MDR1 expres-
sion. Indeed, MDR1 transcription has been targeted with Ect-
einascidin 743 in pre-clinical studies (5) and more recently by
modulation of the nuclear receptor SXR (6). Strategies involv-
ing antisense and transcriptional decoy (7) and the use of
anti-MDR1 mRNA hammerhead ribozymes have also been
suggested (8).
Stresses such as short-term exposure to cytotoxic drugs re-
sults in the up-regulation of MDR1 mRNA levels in many cell
lines (9–13) and in human metastatic sarcomas in vivo (14).
This is frequently due to transcriptional activation of the
MDR1 gene and has been reported in many cell lines after
different physical and chemical stimulations and in cells se-
lected for resistance to a variety of cytotoxic drugs (5, 9, 10, 15,
16). In cell lines selected for drug resistance, increased MDR1
gene expression is also the result of amplification of the MDR1
locus and the appearance of self-replicating episomes (4). Gene
rearrangements that constitutively activate MDR1 transcrip-
tion have also been associated with refractory acute lympho-
cytic leukemia (17, 18).
Although regulation due to changes in the MDR1 mRNA
stability (19), P-glycoprotein turnover (20), or trafficking (21)
have been suggested, transcriptional regulation is widely con-
sidered to be the key step accounting for the complex spatio-
temporal pattern of expression in vivo (22, 23). It has also
generally been assumed that up-regulation of MDR1 mRNA
leads to an increase in P-glycoprotein. For example, human
renal carcinoma (16) and rat liver cells (24) up-regulate both
MDR1 mRNA and P-glycoprotein following different stresses
and are consequently transiently resistant to vinblastine.
In this study, we show that in K562 leukemic cells the levels
of MDR1 mRNA increase in a dose- and time-dependent man-
ner upon transient exposure to a variety of cytotoxic drugs.
However, in contrast to the general prevailing models, we show
that this is due to stabilization of mRNA and not because of
transcriptional activation. Furthermore, the newly stabilized
mRNA is not translated and so does not result in expression of
P-glycoprotein and drug efflux. Only on subsequent long-term
selection for drug resistance does the stabilized mRNA associ-
ate with polyribosomes, permitting translation of P-glycopro-
tein and drug efflux. The finding that drug resistance is a
two-step post-transcriptional process, mediated by changes in
both MDR1 mRNA stability and translation, suggests new
possibilities for treatment regimes to circumvent MDR in
leukemia.
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EXPERIMENTAL PROCEDURES
Cell Lines and Culture—K562, CCRF-CEM, and MANN cells were
cultured in RPMI 1640 medium (Invitrogen) with 10% fetal calf serum
and 2 mM L-glutamine; KB-V1 cells (25) were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen) with 20% fetal calf serum and
110 M vinblastine (Sigma). All drugs were obtained from Sigma. For
transient drug treatments (inductions), exponentially growing cells
were seeded at 1  106 cells/ml and incubated with drug for the
indicated times. The drug concentrations used were determined previ-
ously to cause macroscopic changes in cell morphology, indicative of
cytotoxic stress, such as swelling, and changes in shape and granular-
ity, in greater than 50% of cells. Unless otherwise stated, drug induc-
tions were for 3 days using 3.4 nM doxorubicin, 22 M vinblastine, 2.5
nM colchicine, 1.34 M colcemid, or 100 M cytarabine. Drug-resistant
K562 sublines were obtained in a one-step selection by exposure to
concentrations of the following cytotoxic drugs, which had been shown
to result in 99.9% cell death after 14 days in culture in preliminary
experiments: 40 pM colchicine, 30 pM doxorubicin, or 25 M 1--D-
arabinofuranosylcytosine (cytarabine). Lines resistant to these concen-
trations of drug were designated KC40, KD30, and KA25 lines,
respectively.
Determination of mRNA Expression by Semi-quantitative and Real-
time RT-PCR—RNA was prepared from cells by RNAzol extraction
(Biogenesys, Poole, United Kingdom), reverse-transcribed (Roche Mo-
lecular Biochemicals), and amplified by PCR. Semi-quantitative RT-
PCR estimation of MDR1 mRNA levels was performed as described
(26). Real-time quantitative PCR (Taqman; PerkinElmer Life Sciences)
used the following primers within the MDR1 coding sequence: sense,
5-TTGTTCAGGTGGCTCTGGAT-3; antisense, 5-CTGTAGACAAAC-
GATGAGCTATCACA-3; and probe, 5-AGGCCAGAAAAGGTCGGAC-
CACCA-3. Taqman Universal PCR Master Mix and control amplimers
for GAPDH and 18 S ribosomal RNAs were used as recommended by
the supplier (PerkinElmer Life Sciences). Results were collected and
analyzed with an ABI Prism 7700 sequence detection system
(PerkinElmer Life Sciences) as follows: the PCR cycle number that
generated the first fluorescence signal above a threshold (threshold
cycle, CT; 10 standard deviations above the mean fluorescence gener-
ated during the baseline cycles) was determined, and a comparative CT
method was then used to measure relative gene expression. The follow-
ing formula was used to calculate the relative amount of the transcript
in the sample and normalized to an endogenous reference (GAPDH or
18 S rRNA): 2CT, where CT is the difference in CT between the gene
of interest and GAPDH or 18 S rRNA, and CT for the sample  CT
of the actual sample  CT of the lowest expressing sample.
Determination of RNA Half-lives—K562, KC40, and KD30 cells were
incubated with 12.5 g/ml actinomycin D to inhibit transcription. This
concentration of actinomycin D was determined empirically in a series
of pilot experiments as that which inhibited greater than 95% of
[3H]uridine incorporation in both the naı¨ve and drug-resistant K562
cell lines, and thus nascent transcription, within 1 h (27). Cells were
harvested at different times after actinomycin D addition, and total
RNA was isolated as above. Total RNA, or the poly(A) fraction isolated
by using an Oligotex kit (Qiagen), was used in real-time Taqman
RT-PCR assays. In addition, Northern blots (28) of 10 g of total RNA
from the above samples were hybridized with probes derived from
gene-specific sequences from the MDR1, GAPDH, Id2, or RAR- genes
(29, 30). Hybridization signals were quantified with a PhosphorImager
(Amersham Biosciences).
Genomic DNA and Southern Blotting—Genomic DNA was isolated
from cells by proteinase K digestion and phenol/chloroform extraction,
digested with EcoRI, Southern blotted, and hybridized to nick-trans-
lated radioactive probes by standard procedures (28). Probes were de-
rived from the MDR1 5-end region (975-bp PstI fragment comprising
the transcription start point, 5-untranslated region, and first intron)
(31) and the -globin locus (3.0-kb EcoRI fragment containing DNase I
hypersensitive site V) (32). -Globin to MDR1 ratios were obtained by
quantitation using a PhosphorImager.
Nuclear Run-on and Luciferase Transcription Assays—Nuclei were
prepared from naı¨ve, drug-induced, or drug-resistant K562 sublines as
described (27). Nuclear run-on transcription and hybridization methods
have been described elsewhere (33). For the MDR1 promoter-luciferase
transcriptional assays, K562, KC40, and KD30 cells were transiently
transfected with pMDR1(1202), carrying the luciferase reporter gene
from pGL2B (Promega, Madison, WI) under the control of MDR1 pro-
moter (34), together with pEFlacZ carrying the bacterial -galactosid-
ase gene under the control of the EF1 promoter. After 2 days, cells
extracts were prepared, and luciferase activity was determined with a
luciferase assay system (Promega) and normalized against -galacto-
sidase expression (28). The AP-1-dependent luciferase reporter plasmid
(pAP1-luc), containing four tandem copies of the TPA-responsive ele-
ment consensus motif TGACTCA coupled to the 36 to 37 rat prolac-
tin minimal promoter (35), was cotransfected with pEFlacZ into K562
and KD30 cells. When indicated, cells were stimulated with 20 ng/ml
phorbol 12-myristate 13-acetate (Sigma) during the last 12 h, and
luciferase and -galactosidase expression were measured as above.
Transfections were by electroporation using a Bio-Rad gene pulser
(Bio-Rad) with 5  106 cells essentially as described (28).
Measurement of Cell Surface P-glycoprotein by Flow Cytometry—
Analysis of surface P-glycoprotein expression was by flow cytometry
using the fluorescently labeled monoclonal antibody UIC2 (Immuno-
tech, Marseille, France), essentially as described (36), using a Becton
Dickinson Flow Cytometer (BD Biosciences). Live cells were detected by
exclusion of propidium iodide. Drug-induced cells were monitored 1, 2,
3, and 4 days after drug addition. Where indicated, single cells were
sorted into 96-well plates after UIC2 staining at a density of one cell per
well by a FACS Vantage (BD Biosciences) and clonally expanded.
Western Blot Analysis—Crude cell membrane fractions were pre-
pared from 1  108 cells essentially as described (37), with minor
modifications. Briefly, cells were lysed with a hypotonic buffer (50 mM
mannitol, 50 mM Tris-HCl, pH 7.4, 2 mM EGTA) and centrifuged at a
low speed (500  g) to pellet nuclei and associated membranes such as
endoplasmic reticulum and Golgi apparatus (plasma membrane-de-
pleted fraction). The supernatant from the low speed fractionation was
further centrifuged at 100,000  g to obtain the plasma membrane-
enriched fraction. Plasma membrane-enriched and -depleted fractions
(200 g) were separated by SDS-PAGE, and proteins were transferred
electrophoretically to Immobilon membranes (Millipore, Watford,
United Kingdom). Filters were incubated overnight at 4 °C with 0.1
g/ml of the anti-P-glycoprotein monoclonal C219 (Cis-Bio Interna-
tional, Gif-Sur-Yvette, France) or 1:1000 anti-Na/K-ATPase 2 sub-
unit, clone IID8, (Affinity Bioreagents Inc., Golden, CO) in 5 g/100 ml
skimmed milk phosphate-buffered saline containing 0.1 g/100 ml
Tween 20. Protein was visualized by enhanced chemiluminescence
(Amersham Biosciences) after incubating with and horseradish perox-
idase-conjugated goat and mouse IgG secondary antibody (1/1000)
(Dako, Ely, United Kingdom).
De Novo Protein Synthesis—Incorporation of [35S]Met in nascent
proteins was determined by trichloroacetic acid precipitable counts,
following standard procedures (38).
Sucrose Gradient Density Centrifugation and Detection of RNA
across Polysome Profiles—Extracts of drug-induced K562, KC40, and
MANN cells, sucrose gradient centrifugation, and RNA extraction fol-
lowed standard procedures (39). Where indicated, buffers contained 20
mM EDTA. Isolated RNA was precipitated with 3 M LiCl and resus-
pended in 10 l of water. Detection of MDR1 mRNA was by RT-PCR as
described above.
RESULTS
MDR1 mRNA Is Up-regulated in Drug-induced and Drug-
resistant K562 Cells—The myeloid leukemia-derived cell line
K562 expresses very low levels of MDR1 mRNA, barely detect-
able by standard RT-PCR assays (Fig. 1A), although readily
determined by a more sensitive method like real-time RT-PCR
using poly(A) mRNA (data not shown). K562 cells responded
to short-term exposure (drug induction) to several different
cytotoxic drugs (doxorubicin, colchicine, colcemid, vinblastine,
and cytarabine) by up-regulating MDR1 mRNA levels (Fig.
1A). Real-time RT-PCR showed a 30- to 100-fold increase in
MDR1 mRNA levels in drug-induced cells compared with naı¨ve
(not exposed to drug) K562 cells (data not shown). This effect
was due to the cytotoxic drug, because the increase in MDR1
mRNA was both time- and dose-dependent (Fig. 1B).
To generate K562 sublines resistant to low levels of drugs,
three cytotoxic drugs with different modes of action were used,
colchicine (which binds tubulin and prevents mitosis), doxoru-
bicin (a DNA intercalating agent), and cytarabine (a pyrimi-
dine analogue). A one-step drug selection resulted in the gen-
eration of resistant pools of clones (see “Experimental
Procedures”). These lines were called KC40, KD30, and KA25
(colchicine-, doxorubicin-, and cytarabine (araC)-resistant, re-
spectively). MDR1 mRNA was substantially up-regulated in
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each of these lines (Fig. 1A), shown by real-time RT-PCR to be
between 2- and 5-fold greater than the levels found in the 3-day
drug-induced cells (data not shown). Thus, both drug induction
and selection for drug resistance result in substantial increases
in steady-state MDR1 mRNA levels, independent of the mode
of action of the drug.
Up-regulation of MDR1 mRNA Is Not Due to Gene Amplifi-
cation, Gene Rearrangement, or Transcriptional Activation—
Gene amplification is a common mechanism for the up-regula-
tion of MDR1 mRNA in cell lines (4) and is normally
accompanied by rearrangements and deletions in the amplified
locus. Genomic DNA from drug-resistant (KC40 and KD30)
cells had the same MDR1 gene copy number as the parental
line K562, thus no detectable amplification or rearrangements
of the locus had occurred (Fig. 2A).
To determine whether MDR1 mRNA up-regulation was due
to transcriptional activation (40), we used two different ap-
proaches. We initially used a gene reporter assay in which an
MDR1 promoter fragment was placed upstream of the lucifer-
ase reporter gene (34). This reporter plasmid has been used
previously to demonstrate transcriptional activation of MDR1
in, among others, human colon carcinoma SW620 cells (34).
Luciferase expression was equivalent in naı¨ve (not drug-
treated) and all of the drug-resistant K562 lines (Fig. 2B),
suggesting that there is no promoter up-regulation. As AP-1
plays a role in the transcriptional activation of MDR1 (41), and
because K562 cells resistant to etoposide (another P-glycopro-
tein substrate) have up-regulated levels of c-jun and c-fos
mRNAs and increased AP-1 binding activity (42, 43), it was
necessary to exclude the possibility that the AP-1 pathway had
been inactivated in these cells. To do this we used a reporter
plasmid, pAP1-luc, in which the luciferase gene expression was
driven by four human collagenase TPA-responsive elements
and the minimal rat prolactin promoter (35). This TPA-respon-
sive element has been used in numerous studies because of its
high affinity for the AP-1 complex, and, as expected, transient
transfection in Jurkat T-cells results in an increase of lucifer-
ase activity upon TPA activation (35), which increases MDR1
gene expression in several cell lines, including K562 cells (44).
Naı¨ve and drug-resistant cells transiently transfected with
pAP1-luc produced similar levels of luciferase activity, both
before and after TPA activation (Fig. 2C). Thus, the pathway
responsible of activating AP-1 is equally functional in both
naı¨ve and drug-resistant K562 cells, and the lack of transcrip-
tional activation of the MDR1 promoter in drug-resistant cells
cannot be due to a lack of AP-1 functionality.
To confirm that transcriptional activation of the MDR1 pro-
moter is not responsible for MDR1 mRNA up-regulation we
also studied the MDR1 promoter in its native chromosomal
context by nuclear run-on experiments. Despite the increase in
steady-state MDR1 mRNA levels, transcription initiated from
the MDR1 promoter was low compared with transcription from
other control genes (e.g. GAPDH, -actin, or -globin) and did
not increase significantly in drug-resistant or drug-induced
cells (data not shown). Thus, transcriptional activation does
not appear to be responsible for the up-regulation of MDR1
mRNA in K562 cells following drug induction or upon selection
for drug resistance.
Up-regulation of MDR1 Is Due to mRNA Stabilization—
Because the increase in steady-state MDR1 mRNA was not due
to de novo mRNA synthesis, we asked whether changes in the
rates of mRNA decay might be involved. To determine the
half-lives of MDR1 mRNA in naive, drug-induced and drug-
resistant cells, we treated cells with actinomycin D to inhibit
transcription (see “Experimental Procedures”). MDR1 mRNA
from naı¨ve K562 cells had a very short half-life (approximately
FIG. 1. MDR1 mRNA is up-regulated in drug-induced and drug-resistant K562 cells. MDR1 and GAPDH transcripts were amplified by
RT-PCR and detected by Southern blotting and hybridization with specific internal oligonucleotide probes. A, left hand lane shows naı¨ve K562 cells
(not treated with drug), middle lanes show K562 cells transiently induced with doxorubicin (D), cytarabine (A), colchicine (C), colcemid (CD), or
vinblastine (V) for 3 days; right hand lanes show K562 cells selected for resistance to doxorubicin (KD30, KD), cytarabine (KA25, KA), or colchicine
(KC40, KC). KBV1, human KB epidermoid carcinoma line. B, dose-time response for induction of MDR1 mRNA by colcemid using concentrations
of 0.1, 1.0, and 10.0 M.
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1 h) determined by real-time RT-PCR (Fig. 3A). In contrast,
MDR1 mRNA half-life values for doxorubicin- and colchicine-
resistant K562 cells were 12–16 h (Fig. 3A). This was confirmed
by Northern analysis (Fig. 3B) and is in good agreement with
the 14-h half-life reported for another independently derived
doxorubicin-resistant K562 line (K562/ADR) (45). Drug-in-
duced K562 cells also had a long MDR1 mRNA half-life (Fig.
3A). The half-lives of other short-lived messages, such as Id2
and RAR-, were confirmed to be 1–2 h as reported previously
(29, 30) in both naı¨ve and drug-resistant K562 cells (Fig. 3C).
Similarly, the half-life of a long-lived message (GAPDH) was
also unchanged in drug-resistant cells (20–24 h in both naı¨ve
K562 and KD30 cells) (Fig. 3B). Thus, the stabilization of the
MDR1 mRNA is specific and not a general phenomenon affect-
ing other short-lived mRNAs. In conclusion, up-regulation of
MDR1 mRNA levels following exposure to drugs, after either a
transient induction or drug selection, is primarily due to a
specific increase in mRNA stability.
Drug Induction of MDR1 mRNA Does Not Lead to P-glyco-
protein Expression—Transient exposure to cytotoxic drugs
(drug induction) led to an increase in MDR1 mRNA levels
through mRNA stability. This observation led us to ask
whether MDR1 mRNA up-regulation was accompanied by an
increase in P-glycoprotein expression. Cell surface expression
of P-glycoprotein was measured by flow cytometry using the
P-glycoprotein-specific monoclonal antibody UIC2 (36). There
was no significant increase in UIC2-positive cells following
drug induction at any stage during the 4-day incubation period
compared with naı¨ve K562 cells. In contrast, cells selected for
resistance to the P-glycoprotein substrates colchicine (KC40
FIG. 2. Increased MDR1 mRNA levels are not due to gene am-
plification or transcriptional activation. A, Southern blot analysis
of the MDR1 and -globin loci of naı¨ve (untreated) and drug-resistant
(KC40 and KD30) K562 cells. The KB-V1 cell line was used as a positive
control for amplification and rearrangement of the MDR1 locus; arrows
show the positions of rearranged MDR1 fragments in this cell line. B,
transient expression of a luciferase reporter gene driven by the MDR1
promoter was measured after cotransformation of naı¨ve and drug-
resistant (KC40 and KD30) cells with pMDR1(1202) and a bacterial
-galactosidase reporter gene driven by the constitutive EF1 promoter
(pEFlacZ). Luciferase activity was normalized to -galactosidase activ-
ity, and the data are shown as transcription relative to naı¨ve K562 cells
2 days after transfection. Data show the average and S.D. from three
independent experiments. C, AP-1 is not involved in the up-regulation
of MDR1 mRNA in drug-resistant (KD30) cells. The AP-1-dependent
luciferase reporter plasmid (pAP1-luc), containing four tandem copies
of the TPA-responsive element coupled to the rat prolactin minimal
promoter, was cotransfected with pEFlacZ into K562 and KD30 cells
(clear bars). Cells were stimulated with 20 ng/ml phorbol 12-myristate
13-acetate during the last 12 h, and luciferase and -galactosidase
expression were measured as above (filled bars).
FIG. 3. Increased MDR1 mRNA levels are due to an increase in
mRNA half-life. A, MDR1 mRNA decay pattern after actinomycin D
addition to naı¨ve (white circle), drug-induced (black square), and drug-
resistant (white triangle, KC40; black triangle, KD30) K562 cells ob-
tained by RT and real-time quantitative PCR. A representative drug
induction (with vinblastine) is shown. MDR1 mRNA half-lives were 1 h
for the naı¨ve and greater than 10 h for drug-induced and -resistant
cells. B, mRNA decay pattern of K562 (white symbol) and KD30 (black
symbols) cells was followed by Northern analysis (using ten g of total
RNA) and hybridization with GAPDH (circles)- and MDR1 (triangle)-
specific probes. The GAPDH mRNA half-life was 20–24 h in both naı¨ve
and drug-resistant cells, and the half-life of MDR1 mRNA was 15–20 h
in KD30 cells. Similar half-lives were obtained for colchicine-resistant
KC40 cells (data not shown). MDR1 message was undetectable by
Northern hybridization in naı¨ve K562 cells. C, mRNA decay analyzed
by Northern analysis and hybridization to probes for other short-lived
messages (circles, Id2; triangles, RAR-a) in naı¨ve K562 (white symbols)
and doxorubicin-resistant KD30 (black symbols) cells. The half-lives of
the transcripts (1–2 h) were similar in each cell type. Results from
KC40 cells were essentially the same (data not shown).
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cells) or doxorubicin (KD30 cells) showed a large (10- to 100-
fold) increase in UIC2 reactivity, indicating the presence of
active P-glycoprotein on the cell surface. Cells selected for
resistance to cytarabine (KA25 cells), which is not transported
by P-glycoprotein, showed much lower levels of surface P-gly-
coprotein expression than the KC40 and KD30 cells, despite
having similar MDR1 mRNA levels. Only 40% of cytarabine-
resistant (KA25) cells expressed surface P-glycoprotein, con-
sistent with the fact that resistance to cytarabine is known to
be mediated by other P-glycoprotein-independent mechanisms
(11) (Fig. 4A).
The Absence of P-glycoprotein at the Cell Surface Is Not Due
to a Defect in Protein Trafficking—Because the assay above
detects only active P-glycoprotein in the plasma membrane, it
was necessary to exclude the possibility that P-glycoprotein
was expressed in drug-induced cells, but either inserted in the
plasma membrane in an inactive form or accumulated intra-
cellularly. Cell membranes from naı¨ve, drug-induced, and
drug-resistant K562 cells were analyzed for P-glycoprotein ex-
pression by immunoblotting using the monoclonal antibody
C219. A band of 190 kDa, corresponding to mature P-glyco-
protein, was detected in the plasma membrane-enriched frac-
tion from drug-resistant lines but not from the naı¨ve or drug-
induced cells (Fig. 4B). P-glycoprotein was also absent from
plasma membrane-depleted fractions (i.e. nuclear and rough
endoplasmic reticulum) of these cells, indicating that the pro-
tein was not retained intracellularly (Fig. 4B). The intensity of
the C219-specific band was consistent with the level of UIC2
binding (Fig. 4A). Thus, although drug-induced and drug-resis-
tant cells express MDR1 mRNA, only drug-resistant cells are
able to express P-glycoprotein from MDR1 mRNA.
MDR1 mRNA-positive Cells That Cycle Normally Can Lack
P-glycoprotein—Because transient treatment with cytotoxic
drugs led to cell cycle arrest, it was necessary to exclude the
possibility that inhibition of cell cycle progression was respon-
sible for the failure to express P-glycoprotein. The colchicine
analogue colcemid was used, because its microtubule depoly-
merizing activity can be relieved following extensive washes of
the cells (46). K562 cells were induced for 4 days with colcemid,
which completely arrested the cell cycle and up-regulated
MDR1 mRNA (Fig. 5, A and B). The washed cells were trans-
ferred to drug-free medium, where they remained quiescent for
a further 2–3 days before proliferating at the same rate as
untreated cells (Fig. 5A). The colcemid-induced increase in
MDR1 mRNA persisted for at least 19 days after drug with-
drawal (Fig. 5B), yet this did not lead to the synthesis of
FIG. 4. Up-regulation of MDR1 mRNA in drug-induced K562 cells does not lead to expression of P-glycoprotein. A, flow cytometric
analysis of surface P-glycoprotein expression using the UIC2-phycoerythrin-conjugated antibody (filled peak) and the corresponding IgG isotype
control (clear peak). For naı¨ve and drug-induced cells, the IgG and UIC2 peaks overlap, showing that active P-glycoprotein is not present at the
cell surface. A representative drug-induction experiment with colchicine after 3 days is shown. Qualitatively similar data were obtained with other
drugs (vinblastine, colcemid, doxorubicin, or cytarabine) or if measured 1, 2, or 4 days after drug induction (data not shown). For the drug-resistant
cell lines KC40 and KD30, UIC2 fluorescence was higher than the IgG control, indicating expression of P-glycoprotein on the surface of the cells.
Approximately 40% of cytarabine-resistant (KA25) cells showed limited P-glycoprotein expression. B, Western blot analysis of P-glycoprotein (P-gp)
in plasma membrane-enriched and -depleted fractions (200 g protein) from K562 naı¨ve (K), drug-induced (D, doxorubicin; A, cytarabine; CD,
colcemid), or drug-resistant cells (KD, KD30; KA, KA25; KC, KC40). An anti-Na/K-ATPase antibody was used as loading control. Drug inductions
were carried out for 3 days.
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P-glycoprotein (Fig. 5C). Therefore, mitotic arrest is not re-
sponsible for the lack of P-glycoprotein expression in drug-
induced cells.
This was further confirmed by studying single-cell-derived
clones from KA25 cells (selected as resistant to the non-P-
glycoprotein substrate cytarabine). Clones from both P-glyco-
protein-expressing (UIC2-positive) and non-expressing (UIC2-
negative) subpopulations (Fig. 4A) (data not shown) were
obtained by flow cytometry sorting. RNA analysis indicated
that the MDR1 transcript was up-regulated in both types of
cells (data not shown). Thus, cell selected for resistance to
cytarabine and growing normally can also express MDR1
mRNA but still fail to express P-glycoprotein. Therefore, cells
that cycle normally, either after drug withdrawal or after se-
lection with a non-P-glycoprotein substrate, can up-regulate
MDR1 mRNA but fail to express P-glycoprotein.
Increased Levels of MDR1 mRNA Do Not Correlate with
P-glycoprotein Levels in Other Cell Types—To test whether the
absence of P-glycoprotein expression in MDR1 mRNA-positive
cells was a phenomenon particular to K562 cells, we studied
the acute lymphocytic leukemia-derived cell line CCRF-CEM.
In contrast to K562 cells, naı¨ve CCRF-CEM cells were found to
have detectable MDR1 mRNA levels, which increased upon
drug induction. No P-glycoprotein was detected in the induced
cells (data not shown). We also studied a non-leukemic-derived
cell line, the EBV-transformed B cell line MANN, in which the
naı¨ve untreated cells express significant levels of MDR1 mRNA
but no P-glycoprotein (binding to UIC2 monoclonal antibody;
data not shown). These cells are also unable to efflux rhoda-
mine 123, a fluorescent P-glycoprotein substrate (47). The lack
of correlation between steady-state MDR1 mRNA and P-glyco-
protein levels in these cell lines suggests that the mechanism
regulating P-glycoprotein expression is not restricted to
K562 cells.
MDR1 mRNA Is Not Associated with Translating Polyribo-
somes in Cells Failing to Express P-glycoprotein—To test
whether the drug-induced MDR1 mRNA had undergone RNA
editing or processing that rendered it untranslatable, the full
MDR1 cDNA from colcemid-induced cells was sequenced and
compared with the sequence deposited in the databases (Gen-
Bank™ accession number M14758). When polymorphisms were
found, they were always confirmed to exist in the MDR1 cDNA
sequence from a drug-resistant K562 cell expressing
P-glycoprotein (KC40). No differences between the mRNA se-
quences were found, showing that the MDR1 mRNA does not
undergo editing or processing during short-term drug exposition
or drug selection, which could account for lack of P-glycoprotein.
Because stress can have a general negative effect on protein
synthesis (48–50) we also measured the rate of incorporation of
[35S]Met into nascent proteins in naı¨ve and drug-induced K562
cells. There was approximately an 8% decrease in the rate of
overall protein synthesis after 24 h in the presence of cytotoxic
FIG. 5. Lack of P-glycoprotein expression by drug-induced K562 cells is not due to cell cycle arrest. A, K562 cells were treated with
colcemid for 4 days and then grown drug-free for a further 14 days (filled circles). The growth curves of naı¨ve (untreated) K562 cells (open circles)
are comparable. B, MDR1 and GAPDH transcripts from the cells were amplified by RT-PCR and detected by Southern blot hybridization using
oligonucleotide probes. C, flow cytometric analysis of surface P-glycoprotein expression in the cells using the UIC2-phycoerythrin-conjugated
antibody (filled peak) and the corresponding IgG isotype control (clear peak). IgG and UIC2 fluorescence signals overlapped, indicating no
P-glycoprotein in the surface of the cells after colcemid withdrawal, despite the presence of MDR1 mRNA.
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drug, which decreased further to 40% after 72 h (data not
shown). Thus, upon treatment with cytotoxic drugs there is a
general decrease in the rate of protein synthesis. However,
although de novo translation is decreased by the drug treat-
ment, this effect is insufficient to account for the complete lack
of expression of P-glycoprotein. To confirm that the absence of
P-glycoprotein expression in drug-induced cells was due to a
failure to translate MDR1 mRNA, we examined MDR1 mRNA
association with polyribosomes. Cell lysates were fractionated
by sucrose gradient ultracentrifugation, and the amount of
MDR1 mRNA in individual fractions was determined by semi-
quantitative PCR (51). In drug-resistant cells, a substantial
portion of MDR1 mRNA was associated with high molecular
weight polyribosomes (toward the bottom of the gradient) in-
dicating that the MDR1 mRNA was efficiently translated.
When ribosomes were dissociated by including EDTA in the
extraction buffer and sucrose gradients, the position of the
MDR1 mRNA shifted toward the lighter (non-polysome) frac-
tions of the gradient, as expected. In contrast, for drug-induced
K562 cells MDR1 mRNA migrated at approximately the same
position as for EDTA-dissociated KC40 cells (top of the gradi-
ent), indicating that in these cells MDR1 mRNA is not associ-
ated with polyribosomes and is not being translated (Fig. 6). To
exclude the possibility that the absence of association between
MDR1 mRNA and polyribosomes is due to a general reduction
in the rate of protein synthesis, caused by the cytotoxic drugs,
the association of MDR1 mRNA with ribosomes was also ex-
amined in P-glycoprotein-negative EBV-transformed B lym-
phocytes (MANN cell line). In these cells, which had not been
exposed to cytotoxic drugs, MDR1 mRNA was not associated
with polyribosomes (Fig. 6). The translational block is, there-
fore, not due to the effect of cytotoxic drugs and represents a
novel mechanism for regulating P-glycoprotein expression.
DISCUSSION
Expression of MDR1/P-glycoprotein in blasts from leukemia
patients has been adversely correlated with the clinical re-
sponse to chemotherapy (2, 3, 52). We have used a K562 leu-
kemic cell model system to study the mechanisms regulating
MDR1 gene expression involved in the acquisition of MDR.
Unexpectedly, we found that in these cells, up-regulation of
P-glycoprotein expression was a two-step process, mRNA sta-
bilization and relief from a translational block.
Three drug-resistant K562 cell lines were developed, resist-
ant to the P-glycoprotein substrates, doxorubicin and colchi-
cine, or to the non-P-glycoprotein substrate, cytarabine. In
contrast to many previous studies, we developed these lines by
just a single-step selection to very low doses of cytotoxic drug,
rather than the traditional stepwise selection at increasing
drug concentrations. This enabled us to work at drug concen-
trations and levels of drug resistance closer to those found in
the clinic and avoided amplification and rearrangements of the
MDR1 locus frequently found in highly resistant cell lines but
never documented in vivo (Fig. 2A) (1).
As expected, drug-resistant K562 lines, as well as naı¨ve
K562 cells transiently exposed to a range of cytotoxic agents,
up-regulated steady-state MDR1 mRNA levels (Fig. 1A). This
effect was independent of the mode of action of the drug. Sim-
ilarly, it has been reported that heat shock, UV radiation,
arsenate, or sodium butyrate also induces MDR1 gene expres-
sion in a variety of systems (40). Transcriptional activation is
generally assumed to be the principal mechanism for up-regu-
lating MDR1 gene expression, and several regulatory elements
(AP-1, heat shock element, Sp1, Y-box, CAAT box) have been
identified and characterized in the MDR1 promoter region (40).
In this study we found that in K562 leukemic cells transiently
exposed to drugs or further selected for drug resistance the
increased MDR1 mRNA levels could not be accounted for by
transcriptional activation of the MDR1 promoter (Fig. 2B).
Furthermore, the AP-1-dependent activation of the MDR1 pro-
moter, observed in other cell lines, was not apparent in K562
cells despite the fact that the AP-1 activation pathway by
protein kinase C was shown to be functional in both naı¨ve and
FIG. 6. MDR1 mRNA is not associated with translating polyribosomes in cells failing to express P-glycoprotein. Detection of MDR1
mRNA in fractions from a 15–45% sucrose gradient of cell extracts by semi-quantitative RT-PCR is shown. Fractions (0.5 ml) were collected from
the top of the gradient, and RNA was isolated. Where indicated, ribosomes were dissociated by the inclusion of EDTA in both the extraction and
gradient buffers. A representative induction with colcemid for 3 days is shown. Similar results were obtained after doxorubicin induction. In
drug-resistant cells expressing P-glycoprotein MDR1 mRNA migrates with the heavy (containing polyribosomes) fractions. In both drug-induced
K562 and MANN (EBV-transformed human B lymphocytes) cells, which do not express P-glycoprotein, MDR1 mRNA migrates with the light
fractions lacking polyribosomes, indicating that it is not being translated.
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drug-resistant K562 cells (Fig. 2C). Because K562 cells do not
express the tumor suppressor gene p53 (53), the absence of
transcriptional activation in the cells could, at least in part, be
due to a lack of functional p53, which is known to activate the
MDR1 promoter (54).
In contrast to transcriptional activation, we found that up-
regulation of MDR1 mRNA in K562 cells is due to an increase
in mRNA stability (Fig. 3, A and B). This was specific to the
MDR1 mRNA as the stability of other short-lived mRNA spe-
cies remained unaffected (Fig. 3C). Interestingly, in naı¨ve K562
cells, MDR1 mRNA has a very short half-life (around 1 h),
which, in addition to the low rate of transcription from the
MDR1 gene, can account for the low steady-state levels found
in naı¨ve cells (Fig. 1A). The cis-determinants involved in
mRNA stabilization are usually, but not exclusively, located in
the 3-untranslated region of the transcripts (55). The MDR1
3-untranslated region is short (378 nucleotides) and contains
several potential AU-binding protein recognition sites that
could regulate rapid mRNA decay (55). The short half-life of
MDR1 mRNA in naı¨ve K562 cells contrasts with the few stud-
ies that report a longer half-life, i.e. 8 h in the human hepatoma
cell line HepG2 (56). The MDR1 mRNA half-life increased
10-fold upon transient exposure of cells to cytotoxic drugs and
in the drug-resistant lines (KD30 and KC40) (Fig. 3). Similar
long half-lives have also been described in a K562 line resistant
to doxorubicin (45). The stabilized MDR1 mRNA from drug-
induced K562 cells persisted for several days after the recovery
from the cytotoxic stress but eventually returned to the basal
level of naı¨ve K562 cells (Fig. 5B), consistent with dilution of a
trans-acting stabilizing factor upon cell division to levels below
a functional concentration. One interpretation of the data is
that this putative factor(s) is activated upon drug exposure.
In contrast to other studies using different systems (16, 24),
following transient drug exposure (drug induction) the increase
in steady-state MDR1 mRNA was not accompanied by a par-
allel increase in P-glycoprotein expression in K562 cells (Fig.
4). This effect could, in part, be due to a decrease in the rate of
global protein synthesis due to cytotoxic stress caused by the
drug (48–50). MDR1 mRNA, but no P-glycoprotein, was also
demonstrated in K562 cells after colcemid withdrawal (Fig. 5B)
and in K562 cells resistant to the non-P-glycoprotein substrate
cytarabine (data not shown). In addition, CCRF-CEM cells and
EBV-transformed human lymphocytes do not express P-glyco-
protein despite being MDR1 mRNA-positive (data not shown).
A lack of correlation between MDR1 expression and P-glyco-
protein function has also been reported previously in acute
myeloid leukemia cell lines (57) and human bone marrow
lymphoid cells (58). There is, therefore, a clear lack of correla-
tion between the presence of MDR1 mRNA and P-glycoprotein
in several lymphocyte cell models, showing it is not specific to
K562 cells or the drug treatment regime.
In this study we show that translational regulation plays an
important role in determining the levels of P-glycoprotein ex-
pression. Translational control most likely operates at the level
of initiation, because MDR1 mRNA does not migrate with the
polysome fractions in P-glycoprotein-negative cells. As the se-
quence of MDR1 mRNA from P-glycoprotein-expressing and
non-expressing cells is identical, regulation must involve trans-
acting factors (59, 60). Upon drug selection this translational
block is overcome, enabling the cells to grow in the presence of
the cytotoxic drug.
In summary, the data show that in K562 cells up-regulation
of MDR1 gene expression occurs at two distinctive steps,
mRNA stabilization and translational initiation. That these
two steps are distinct is also illustrated by data obtained with
cytarabine, a cytotoxic drug not transported by P-glycoprotein.
Cytarabine was as effective as the P-glycoprotein substrates in
inducing MDR1 mRNA stabilization, suggesting that this is a
general response to drug-induced stress. Upon selection for
cytarabine resistance, P-glycoprotein was expressed in a sub-
population of cells, in contrast to selection for resistance to
P-glycoprotein substrates where all cells expressed P-glycopro-
tein (Fig. 2A). MDR1 mRNA was up-regulated in clones derived
from both the P-glycoprotein-positive and P-glycoprotein-neg-
ative cells (data not shown) indicating that in these cells the
first step in the acquisition of MDR has occurred. The second
step, relief from the translational block, had also occurred in a
subpopulation of cells. As cytarabine induces apoptosis (61),
and caspase-dependent apoptotic pathways are inhibited in
P-glycoprotein-overexpressing K562 and CCRF-CEM cells (62),
the expression of P-glycoprotein in this subpopulation of cy-
tarabine-resistant cells may indicate that P-glycoprotein con-
fers a selective growth advantage, perhaps through inactiva-
tion of caspase-dependent processes.
These findings have implications for attempts to circumvent
or overcome drug resistance in the clinic, at least for leukemia.
First, the demonstration that MDR1 mRNA levels do not nec-
essarily correlate with P-glycoprotein expression show that
measuring MDR1 mRNA as a clinical surrogate for P-glycopro-
tein-mediated drug resistance is inappropriate. Second, as
drugs themselves can induce stabilization of MDR1 mRNA, the
first necessary step in acquiring P-glycoprotein-mediated drug
resistance, drug treatment regimes should be developed to
minimize this occurrence. Finally, as induction of drug resist-
ance involves two specific steps, stabilization of MDR1 mRNA
and subsequent overcoming of a translational block, each of
these steps provides novel and potentially specific targets for
circumventing drug resistance in the clinic.
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